A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 20 11 2019
revised: 26 06 2020
accepted: 17 07 2020
pubmed: 28 7 2020
medline: 16 4 2021
entrez: 27 7 2020
Statut: ppublish

Résumé

Through this multi-institutional study, we aimed to retrospectively evaluate the safety and efficacy of repeated stereotactic body radiation therapy (SBRT) for intrahepatic recurrent hepatocellular carcinoma (HCC). Between 2005 and 2017, 709 patients with 835 HCCs underwent SBRT; those treated with repeated SBRT were eligible. The median prescribed dose was 40 Gy in 5 fractions. Eighty-one patients with 189 tumors underwent repeated SBRT (≥ 2 courses [median 2 times; range, 2-5 times]). The median follow-up periods from the first to the second SBRT were 41.5 (range, 12-99) and 20 (range, 1-81) months, respectively. The median interval between the first and second SBRT was 18 (range, 3-74) months. The 5-year local recurrence rate was 6.3% (95% confidence interval [CI], 2.3%-13.4%). The 5-year overall survival (OS) and liver-related death rates from the first SBRT were 60.4% (95% CI, 47.0%-73.8%) and 32.9% (95% CI, 20.3%-46.0%), respectively, and the 3-year rates from the second SBRT were 61.0% (95% CI, 49.9%-75.2%) and 34.5% (95% CI, 20.6%-48.9%), respectively. The frequency of grade 3 toxicity was not significantly different between the first and second SBRT (first: 11% [95% CI, 5.2%-20%]; second: 15% [95% CI, 7.9%-24%]; P = .48). Among 39 patients with no intrahepatic recurrence for 1 year after the first and second SBRT, the deterioration in liver function after the first and second SBRT was not significantly different; the albumin-bilirubin score increased 1 year after the first versus second SBRT (first, 0.143 ± 0.23; second, 0.195 ± 0.38; P = .48). Multivariate analysis revealed that the intrahepatic recurrence-free interval was the only significant factor for OS. Repeated SBRT for intrahepatic recurrent HCC resulted in high local control with safety and a satisfactory OS comparable with that of other curative local treatments for patients with well-preserved liver function.

Identifiants

pubmed: 32712256
pii: S0360-3016(20)31453-X
doi: 10.1016/j.ijrobp.2020.07.034
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1265-1275

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Tomoki Kimura (T)

Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima City, Japan. Electronic address: tkkimura@hiroshima-u.ac.jp.

Atsuya Takeda (A)

Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura City, Japan.

Yuichiro Tsurugai (Y)

Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura City, Japan.

Reo Kawano (R)

Center For Integrated Medical Research, Hiroshima University Hospital, Hiroshima City, Japan.

Yoshiko Doi (Y)

Department of Radiation Oncology, Hiroshima High-Precision Radiotherapy Cancer Center (HIPRAC), Hiroshima City, Japan.

Yohei Oku (Y)

Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura City, Japan.

Kazunari Hioki (K)

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima City, Japan.

Hideharu Miura (H)

Department of Radiation Oncology, Hiroshima High-Precision Radiotherapy Cancer Center (HIPRAC), Hiroshima City, Japan.

Yasushi Nagata (Y)

Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima City, Japan; Department of Radiation Oncology, Hiroshima High-Precision Radiotherapy Cancer Center (HIPRAC), Hiroshima City, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH